Patents by Inventor Dirk Eulberg

Dirk Eulberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL USE OF SPIEGELMERS
    Publication number: 20090192100
    Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.
    Type: Application
    Filed: May 4, 2006
    Publication date: July 30, 2009
    Inventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
  • Vasopressin-Binding L-Nucleic Acid
    Publication number: 20090181909
    Abstract: The invention relates to a vasopressin-binding nucleic acid, characterized in that the nucleic acid has a Box 1 segment The and a Box 2 segment, Box 1 having the sequence GAGS, in which W=A or U, preferably W=U, and Box 2 having a sequence comprised of approximately 18 to 24 nucleotides, preferably 21 nucleotides, and a group (G)n being contained four times in the sequence, whereby n=2, 3 or 4.
    Type: Application
    Filed: November 29, 2005
    Publication date: July 16, 2009
    Applicant: Noxxon Pharma AG
    Inventors: Werner Purschke, Dirk Eulberg, Sven Klussmann, Ingo Rohl, Axel Vater
  • MCP-1 Binding Nucleic Acids And Use Thereof
    Publication number: 20090156542
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to MCP-1, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.
    Type: Application
    Filed: November 29, 2008
    Publication date: June 18, 2009
    Applicant: NOXXON PHARMA AG
    Inventors: WERNER PURSCHKE, FLORIAN JAROSCH, DIRK EULBERG, SVEN KLUSSMANN, KLAUS BUCHNER, CHRISTIAN MAASCH
  • Nucleic acids specifically binding bioactive ghrelin
    Publication number: 20070031840
    Abstract: The present invention is related to a nucleic acid specifically binding bioactive ghrelin, more preferably n-octanoyl ghrelin, and its use for the diagnosis of grelin mediated diseases and disorders.
    Type: Application
    Filed: November 10, 2004
    Publication date: February 8, 2007
    Applicant: NOXXON Pharma AG
    Inventors: Sven Klussmann, Steffen Helmling, Dirk Eulberg, Christian Maasch, Klaus Buchner
  • Ghrelin binding nucleic acids
    Publication number: 20060257867
    Abstract: The present invention is related to an antagonist of ghrelin, wherein the antagonist is a nucleic acid, and whereby preferably the nucleic acid is binding to ghrelin.
    Type: Application
    Filed: August 1, 2003
    Publication date: November 16, 2006
    Inventors: Steffen Helmling, Dirk Eulberg, Christian Maasch, Sven Klussmann
  • Ghrelin binding nucleic acids
    Publication number: 20060258607
    Abstract: The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight consecutive nucleotides, whereby a 3?-terminal stretch of nucleotides of the first stretch Box A hybridises with the second stretch Box B, whereby upon hybridisation a first double-stranded structure is formed, whereby such first double-stranded structure comprises a bulge.
    Type: Application
    Filed: April 7, 2006
    Publication date: November 16, 2006
    Applicant: NOXXON Pharma AG
    Inventors: Florian Jarosch, Dirk Eulberg, Christian Maasch, Steffen Helmling, Sven Klussmann